Nyrada Quarterly Activities Report & Appendix 4C

Highlights:
•Nyrada successfully completes Good Laboratory Practice safety studies of lead drug candidate NYR-BI03.
•Preclinical efficacy study showed NYR-BI03 provided an 86% cardioprotective effect following myocardial ischemic-reperfusion injury.
•Australian based Contract Research Organisation engaged to conduct first-in-human Phase I clinical trial for NYR-BI03 commencing in late 2024.
•Cash position of AU$2.98 million as at 30 September 2024. AU$1.38 million R&D tax rebate expected in late 2QFY2025.